Risk adjusted net present value: What is the current valuation of Vigil Neuroscience’s Iluzanebart?

Iluzanebart is a monoclonal antibody commercialized by Vigil Neuroscience, with a leading Phase III program in Neurodegenerative Diseases.

Ongoing study investigates if ultra-processed foods influence brain chemistry and obesity risk in young adults

Researchers are exploring how diets high in ultra-processed foods influence reward processing in the brain and potentially lead to increased food intake and obesity in

November 10, 2023

Wood cookstove use linked to gastric cancer risk

Researchers conducted a population-based study with a case–control design in rural areas of Honduras in Central America to examine whether wood cookstove use by indigenous

October 4, 2023

Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria – Biotech Investments

Relief Therapeutics Holding SA / Key word(s): Study results 04-Oct-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The

October 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.